Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2009

01.12.2009 | Epidemiology

Accuracy of self-reported breast cancer among women undergoing mammography

verfasst von: Linn Abraham, Berta M. Geller, Bonnie C. Yankaskas, Erin J. A. Bowles, Leah S. Karliner, Stephen H. Taplin, Diana L. Miglioretti

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

This study estimated the sensitivity and specificity of self-reported breast cancer and their associations with patient factors and pathologic findings using data from the Breast Cancer Surveillance Consortium. We included 24,631 women with and 463,804 women without a prior diagnosis of breast cancer who completed a questionnaire (including breast cancer history) at participating US mammography facilities between 1996 and 2006. We determined “true” cancer status using cancer registries and pathology databases. Multivariable logistic regression models were used to examine associations with patient factors and pathologic findings. Sensitivity of self-reported breast cancer was higher for women with invasive cancer (96.9%) than for those with ductal carcinoma in situ (DCIS) (90.2%). Specificity was high overall (99.7%) but much lower for women with a history of lobular carcinoma in situ (LCIS) (65.0%). In multivariable models, women reporting older ages, a nonwhite race/ethnicity, or less education had lower sensitivities and specificities. Sensitivity was reduced when there was evidence of prior DCIS, especially when this diagnosis had been made more than 2 years before questionnaire completion. Women reporting a family history of breast cancer had higher sensitivity. Evidence of prior LCIS was associated with lower specificity. The accuracy of self-reported breast cancer depends on the respondent’s characteristics and prior diagnoses. Accuracy is lower among nonwhite women and women reporting less education. There appears to be uncertainty surrounding breast findings such as DCIS and LCIS. These results have important implications for research relying on self-report and for patient communication and care.
Literatur
1.
Zurück zum Zitat Newell SA, Girgis A, Sanson-Fisher RW, Savolainen NJ, Hons BA (1999) The accuracy of self-reported health behaviors and risk factors relating to cancer and cardiovascular disease in the general population: a critical review. Am J Prev Med 17:211–229. doi:10.1016/S0749-3797(99)00069-0 CrossRefPubMed Newell SA, Girgis A, Sanson-Fisher RW, Savolainen NJ, Hons BA (1999) The accuracy of self-reported health behaviors and risk factors relating to cancer and cardiovascular disease in the general population: a critical review. Am J Prev Med 17:211–229. doi:10.​1016/​S0749-3797(99)00069-0 CrossRefPubMed
2.
Zurück zum Zitat Schrijvers CT, Stronks K, van de Mheen DH, Coebergh JW, Mackenbach JP (1994) Validation of cancer prevalence data from a postal survey by comparison with cancer registry records. Am J Epidemiol 139:408–414PubMed Schrijvers CT, Stronks K, van de Mheen DH, Coebergh JW, Mackenbach JP (1994) Validation of cancer prevalence data from a postal survey by comparison with cancer registry records. Am J Epidemiol 139:408–414PubMed
3.
Zurück zum Zitat Bergmann MM, Byers T, Freedman DS, Mokdad A (1998) Validity of self-reported cancers in a prospective cohort study in comparison with data from state cancer registries. Am J Epidemiol 147:556–562PubMed Bergmann MM, Byers T, Freedman DS, Mokdad A (1998) Validity of self-reported cancers in a prospective cohort study in comparison with data from state cancer registries. Am J Epidemiol 147:556–562PubMed
5.
Zurück zum Zitat Parikh-Patel A, Allen M, Wright WE, California Teachers Study Steering Committee (2003) Validation of self-reported cancers in the California Teachers Study. Am J Epidemiol 157:539–545. doi:10.1093/aje/kwg006 CrossRefPubMed Parikh-Patel A, Allen M, Wright WE, California Teachers Study Steering Committee (2003) Validation of self-reported cancers in the California Teachers Study. Am J Epidemiol 157:539–545. doi:10.​1093/​aje/​kwg006 CrossRefPubMed
9.
Zurück zum Zitat Barlow WE, White E, Ballard-Barbash R et al (2006) Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 98:1204–1214PubMedCrossRef Barlow WE, White E, Ballard-Barbash R et al (2006) Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 98:1204–1214PubMedCrossRef
10.
Zurück zum Zitat Ballard-Barbash R, Taplin SH, Yankaskas BC et al (1997) Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. AJR Am J Roentgenol 169:1001–1008PubMed Ballard-Barbash R, Taplin SH, Yankaskas BC et al (1997) Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. AJR Am J Roentgenol 169:1001–1008PubMed
13.
Zurück zum Zitat SAS Institute Inc (2002) SAS/STAT® users guide, version 9. SAS Institute Inc., Cary, NC SAS Institute Inc (2002) SAS/STAT® users guide, version 9. SAS Institute Inc., Cary, NC
15.
Zurück zum Zitat Battaglia TA, Roloff K, Posner MA, Freund KM (2007) Improving follow-up to abnormal breast cancer screening in an urban population. A patient navigation intervention. Cancer 109(2 suppl):359–367. doi:10.1002/cncr.22354 CrossRefPubMed Battaglia TA, Roloff K, Posner MA, Freund KM (2007) Improving follow-up to abnormal breast cancer screening in an urban population. A patient navigation intervention. Cancer 109(2 suppl):359–367. doi:10.​1002/​cncr.​22354 CrossRefPubMed
18.
Zurück zum Zitat Nápoles-Springer AM, Livaudais JC, Bloom J, Hwang S, Kaplan CP (2007) Information exchange and decision making in the treatment of Latina and white women with ductal carcinoma in situ. J Psychosoc Oncol 25:19–36. doi:10.1300/J077v25n04_02 CrossRefPubMed Nápoles-Springer AM, Livaudais JC, Bloom J, Hwang S, Kaplan CP (2007) Information exchange and decision making in the treatment of Latina and white women with ductal carcinoma in situ. J Psychosoc Oncol 25:19–36. doi:10.​1300/​J077v25n04_​02 CrossRefPubMed
19.
20.
Zurück zum Zitat Li CI, Malone KE, Saltzman BS, Daling JR (2006) Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001. Cancer 106:2104–2112. doi:10.1002/cncr.21864 CrossRefPubMed Li CI, Malone KE, Saltzman BS, Daling JR (2006) Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001. Cancer 106:2104–2112. doi:10.​1002/​cncr.​21864 CrossRefPubMed
21.
Zurück zum Zitat Cuzick J, Forbes JF, Sestak I, International Breast Cancer Intervention Study I Investigators et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272–282. doi:10.1093/jnci/djk049 CrossRefPubMed Cuzick J, Forbes JF, Sestak I, International Breast Cancer Intervention Study I Investigators et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272–282. doi:10.​1093/​jnci/​djk049 CrossRefPubMed
Metadaten
Titel
Accuracy of self-reported breast cancer among women undergoing mammography
verfasst von
Linn Abraham
Berta M. Geller
Bonnie C. Yankaskas
Erin J. A. Bowles
Leah S. Karliner
Stephen H. Taplin
Diana L. Miglioretti
Publikationsdatum
01.12.2009
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0375-4

Weitere Artikel der Ausgabe 3/2009

Breast Cancer Research and Treatment 3/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.